C. Seynaeve

1.7k total citations
37 papers, 668 citations indexed

About

C. Seynaeve is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Seynaeve has authored 37 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 13 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Seynaeve's work include BRCA gene mutations in cancer (10 papers), Cancer Treatment and Pharmacology (8 papers) and Breast Cancer Treatment Studies (7 papers). C. Seynaeve is often cited by papers focused on BRCA gene mutations in cancer (10 papers), Cancer Treatment and Pharmacology (8 papers) and Breast Cancer Treatment Studies (7 papers). C. Seynaeve collaborates with scholars based in Netherlands, United States and United Kingdom. C. Seynaeve's co-authors include Jaap Verweij, M. Bontenbal, PHM de Mulder, Ronald de Wit, J.G.M. Klijn, A Bröcker-Vriends, Iris van Oostrom, Aad Tibben, H.J. Duivenvoorden and Rolf H. Sijmons and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

C. Seynaeve

36 papers receiving 636 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Seynaeve Netherlands 16 299 210 168 163 137 37 668
Kentaro Nakao Japan 16 497 1.7× 195 0.9× 149 0.9× 128 0.8× 390 2.8× 55 916
D.B.Y. Fontein Netherlands 16 454 1.5× 139 0.7× 254 1.5× 210 1.3× 246 1.8× 29 767
Emily Glogowski United States 14 97 0.3× 172 0.8× 88 0.5× 89 0.5× 73 0.5× 27 530
John L. Hayward United Kingdom 15 383 1.3× 132 0.6× 310 1.8× 207 1.3× 105 0.8× 20 733
Ilonka Evans United States 11 475 1.6× 126 0.6× 107 0.6× 163 1.0× 76 0.6× 14 921
Álvaro Pinto Spain 15 449 1.5× 76 0.4× 149 0.9× 212 1.3× 159 1.2× 80 827
PA Ganz United States 8 579 1.9× 74 0.4× 256 1.5× 120 0.7× 209 1.5× 26 824
Michaela Onstad United States 10 304 1.0× 83 0.4× 177 1.1× 50 0.3× 90 0.7× 24 736
Leena Vehmanen Finland 16 865 2.9× 128 0.6× 140 0.8× 163 1.0× 78 0.6× 34 1.0k
Niels Kroman Denmark 6 229 0.8× 127 0.6× 237 1.4× 42 0.3× 140 1.0× 8 465

Countries citing papers authored by C. Seynaeve

Since Specialization
Citations

This map shows the geographic impact of C. Seynaeve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Seynaeve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Seynaeve more than expected).

Fields of papers citing papers by C. Seynaeve

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Seynaeve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Seynaeve. The network helps show where C. Seynaeve may publish in the future.

Co-authorship network of co-authors of C. Seynaeve

This figure shows the co-authorship network connecting the top 25 collaborators of C. Seynaeve. A scholar is included among the top collaborators of C. Seynaeve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Seynaeve. C. Seynaeve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vos, Janet R., Maartje J. Hooning, Jan C. Oosterwijk, et al.. (2014). Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. Data Archiving and Networked Services (DANS). 50. 2 indexed citations
2.
Pepels, Manon J., Maaike de Boer, George F. Borm, et al.. (2012). Relevant impact of central pathology review on nodal classification in individual breast cancer patients. Annals of Oncology. 23(10). 2561–2566. 26 indexed citations
3.
Seynaeve, C., Agnes Jager, Rob B. van der Luijt, et al.. (2010). Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.. Journal of Clinical Oncology. 28(15_suppl). 1020–1020. 5 indexed citations
4.
5.
Hamberg, Paul, Jaap Verweij, & C. Seynaeve. (2007). Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy. European Journal of Cancer. 43(10). 1514–1528. 22 indexed citations
6.
Oostrom, Iris van, Hanne Meijers-Heijboer, H.J. Duivenvoorden, et al.. (2006). Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. Annals of Oncology. 17(7). 1090–1095. 36 indexed citations
7.
Oostrom, Iris van, Hanne Meijers‐Heijboer, H.J. Duivenvoorden, et al.. (2006). Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study. Clinical Genetics. 71(1). 35–42. 63 indexed citations
8.
Menke‐Pluymers, Marian B. E., C. Seynaeve, A.N. van Geel, et al.. (2005). [Preventive surgical prcedures for inherited risk of breast cancer].. PubMed. 149(48). 2663–7. 3 indexed citations
9.
Blay, Jean‐Yves, Axel Le Cesne, Jaap Verweij, et al.. (2004). A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours. European Journal of Cancer. 40(9). 1327–1331. 44 indexed citations
10.
Smorenburg, Carolien H., et al.. (2001). Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Research and Treatment. 66(1). 83–87. 63 indexed citations
11.
Verweij, Jaap, W. Ruka, J. Buesa, et al.. (2000). Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.. International Journal of Clinical Oncology. 18. 2081–2086. 30 indexed citations
12.
Verhoog, L.C., E. Berns, Cecile T.M. Brekelmans, et al.. (2000). Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.. PubMed. 18(21 Suppl). 119S–24S. 21 indexed citations
13.
Klijn, J.G.M., Buddy Setyono-Han, M. Bontenbal, C. Seynaeve, & John A. Foekens. (1996). Novel Endocrine Therapies in Breast Cancer. Acta Oncologica. 35(sup5). 30–37. 7 indexed citations
14.
15.
Somers, R., Armando Santoro, Jaco J. Verweij, et al.. (1992). Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer. 28(4-5). 855–857. 4 indexed citations
16.
Seynaeve, C., P.H.M. de Mulder, & Jaap Verweij. (1991). Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear. Pharmacy World & Science. 13(1). 1–6. 12 indexed citations
17.
Seynaeve, C., et al.. (1991). The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clinical Oncology. 3(4). 199–203. 8 indexed citations
18.
Seynaeve, C., Jaap Verweij, & PHM de Mulder. (1991). 5-HT3 receptor antagonists, a new approach in emesis. Anti-Cancer Drugs. 2(4). 343–356. 20 indexed citations
19.
Seynaeve, C., P.H.M. de Mulder, Jaap Verweij, & Richard J. Gralla. (1991). Controlling cancer chemotherapy-induced emesis. Pharmacy World & Science. 13(5). 189–197. 7 indexed citations
20.
Wit, Ronald de, Margot Tesselaar, T.C. Kok, et al.. (1991). Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. European Journal of Cancer and Clinical Oncology. 27(11). 1383–1385. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kentaro Nakao Breakdown of academic impact, for papers by D.B.Y. Fontein Breakdown of academic impact, for papers by Emily Glogowski Breakdown of academic impact, for papers by John L. Hayward Breakdown of academic impact, for papers by Ilonka Evans Breakdown of academic impact, for papers by Álvaro Pinto Breakdown of academic impact, for papers by PA Ganz Breakdown of academic impact, for papers by Michaela Onstad Breakdown of academic impact, for papers by Leena Vehmanen Breakdown of academic impact, for papers by Niels Kroman
Rankless by CCL
2026